Shares of Schering-Plough have fallen 20 percent since the drugmaker said Vytorin failed to meet its primary goal of helping to prevent fatty plaque build-up in carotid arteries than generic cholesterol fighter simvastatin.
Latest Articles
Shares of Schering-Plough have fallen 20 percent since the drugmaker said Vytorin failed to meet its primary goal of helping to prevent fatty plaque buil...
